Xencor faces earnings test after revenue miss rocks biotech By Investing.com

Xencor, a clinical-stage biopharmaceutical company, is set to report its second-quarter results as investors seek signs of revenue recovery after a significant first-quarter miss. Analysts anticipate a loss of $0.81 per share on $17.51 million in revenue, an improvement from the previous quarter but still a substantial year-over-year decline. The company's revenue heavily relies on lumpy partnership milestone payments, making their timing critical, alongside pipeline progress and cash runway.